FDA approves first two interchangeable biosimilars to Regeneron's blockbuster Eylea
Eylea will eventually have competition in the US, as the FDA approved two interchangeable biosimilars. Monday’s approvals for Biocon Biologics’ Yesafili and Samsung Bioepis and Biogen’s Opuviz are based on the companies’ ability …